BRIEF published on 12/06/2024 at 13:22, 1 year 9 months ago Grünenthal Successfully Issues €500 Million Bond Bond Issuance Grünenthal Maturity Profile €500 Million Finance Strategy
PRESS RELEASE published on 12/06/2024 at 13:17, 1 year 9 months ago Grünenthal successfully places new €500 million bond Grünenthal GmbH successfully places new €500 million bond to strengthen capital structure and pursue growth strategy, enhancing flexibility for investments and innovation Growth Strategy Bond Capital Structure Debt Issue Grünenthal GmbH
BRIEF published on 11/27/2024 at 09:40, 1 year 9 months ago Grünenthal annonce le prix d'une obligation de 500 millions d'euros Emission D'obligations 500 Millions D'euros Refinancement De La Dette Grünenthal GmbH Notations De Crédit
BRIEF published on 11/27/2024 at 09:40, 1 year 9 months ago Grünenthal Announces €500 Million Bond Pricing Bond Issuance Credit Ratings Debt Refinancing €500 Million Grünenthal GmbH
PRESS RELEASE published on 11/27/2024 at 09:35, 1 year 9 months ago Grünenthal announces pricing of €500 million bond Grünenthal GmbH announces pricing of €500 million bond to enhance capital structure and maturity profile. New financing to refinance existing debt and repurchase outstanding notes Bond Finance Debt Pricing Grünenthal GmbH
BRIEF published on 03/25/2024 at 09:35, 2 years 5 months ago Grünenthal annonce de solides résultats financiers pour 2023 avec une concentration continue sur la R&D et les acquisitions stratégiques Résultats Annuels Acquisitions Stratégiques Médicaments Grünenthal Investissement En R&D
BRIEF published on 03/25/2024 at 09:35, 2 years 5 months ago Grünenthal Announces Strong Financial Results for 2023 with Continued Focus on R&D and Strategic Acquisitions Pharmaceuticals Annual Results Strategic Acquisitions Grünenthal R&D Investment
PRESS RELEASE published on 03/25/2024 at 09:30, 2 years 5 months ago Grünenthal reports strong 2023 results with record revenue and continued investments in R&D and acquisitions Grünenthal reports strong 2023 results with record revenue and continued investments in R&D and acquisitions Acquisitions 2023 Results Record Revenue R&D Investments Grünenthal
PRESS RELEASE published on 04/25/2023 at 12:51, 3 years 4 months ago Grünenthal GmbH: Grünenthal successfully places new €300 million bond
PRESS RELEASE published on 04/19/2023 at 07:55, 3 years 4 months ago Grünenthal GmbH: Grünenthal announces pricing of €300 million bond
Published on 09/12/2026 at 02:35, 11 hours 7 minutes ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 14 hours 42 minutes ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 15 hours 37 minutes ago Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 16 hours 17 minutes ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 20 hours 42 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 07:30, 6 hours 11 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 15 hours 27 minutes ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 15 hours 31 minutes ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 17 hours 57 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 19 hours 26 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 07:00, 1 day 6 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 6 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 18 hours ago Availability of the 2026 Interim Financial Report
